Biomarker Deals: Terms, Value and Trends, 2008-2018

Table of Contents

Chapter 1 Introduction

Study Goals and Objectives

Reasons for Doing This Study

Scope of Report

Information Sources and Methodology

Intended Audience

Analyst's Credentials

BCC Custom Research

Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

Biomarker Definition and Classification

Biomarker Applications

Biomarker Identification and Detection Technologies

Steps in Biomarker Development

Biomarker Market Analysis and Evaluation

Global Biomarker Market Value and its Segmentation

Oncology-Related Biomarkers Sector

Cardiovascular Diseases Biomarker Sector

Neurological Disorders and Other Diseases Biomarkers Sector

Market Participants in the Biomarkers Space

Chapter 4 Biomarkers Market - Licensing, Acquisitions, Collaborations Deal Analysis

Licensing Deals in the Biomarkers Market, 2008-2018

Licensing Deal Definition and General Structure

Valuation and Payment Structure

Analysis of Licensing Deals in the Biomarkers Market, 2008-2018

Acquisition Deals in the Biomarkers Market, 2008-2018

Acquisition Deal Definition and General Structure

Analysis of Acquisition Deals in the Biomarkers Market, 2008-2018

Partnerships/Collaboration Deals in the Biomarkers Market, 2008-2018

Collaboration Deal Definition and General Structure

Analysis of Partnership/collaboration Deals in the Biomarkers Market, 2008-2018

Analysis of Different Aspects of Licensing, Acquisition and Collaboration Deals in the Biomarkers Market

Analysis of Licensing Deals Structure in the Biomarkers Market, 2008-2018

Analysis of Acquisition Deals Structure in the Biomarkers Market, 2008-2018

Analysis of Collaboration Deals Structure in the Biomarkers Market, 2008-2018

Biomarker Market Participants Active in Licensing, Acquisitions and Partnership/Collaboration Deals, 2008-2018

Qiagen

bioMerieux

MDxHealth

Myriad Genetics

Chapter 5 Impact of Other Markets and Clinical Trials on Licensing, Acquisition and Collaborations in the Biomarkers Market

Cancer Diagnostics as Market Potential for Exosome-Based Diagnostics Product Development

Prostate Cancer as Potential for Biomarker Development

Breast Cancer as Potential for Biomarker Development

Bladder Cancer as Potential for Biomarker Development

Ovarian Cancer as Potential for Biomarker Development

Lung Cancer as Potential for Biomarker Development

CNS Disorders and Neurodegeneration Diseases as Market Potential for Biomarker Development

Cardiovascular Diseases as Market Potential for Biomarker Development

Organ Transplantation as Market Potential for Biomarker Development in Immune Disorders

Clinical Trials as Indicator for Biomarker Market Development

Chapter 6 Patent Review/New Developments

Chapter 7 Market Summary

Chapter 8 Company Profiles

BIOMERIEUX S.A.

INTEGRAGEN SA

MDX HEALTH

MYRIAD GENETICS

PROTAGEN AG

QIAGENList of Tables

Summary Table : Global Biomarkers Licensing, Acquisition and Partnership Deals Market, by Type, 2014-2018

Table 1 : Biomarker Classification

Table 2 : Applications of Biomarkers

Table 3 : Common Techniques Used for Biomarker Identification

Table 4 : Global Biomarkers Market, Through 2023

Table 5 : Global Biomarker Market Share, by Application, 2018

Table 6 : Examples of Cancer Biomarkers for Therapy Selection and Monitoring

Table 7 : Examples of Current Cancer-Associated Antigens/Biomarkers Used in Cancer Diagnosis

Table 8 : Liquid Biopsy Market, 2017 and 2018

Table 9 : Global Cancer Biomarkers Market, Through 2023

Table 10 : Examples of Cardiovascular Biomarkers Used for Clinical Diagnosis

Table 11 : Global Cardiovascular Biomarkers Market, Through 2023

Table 12 : Examples of Neurological Biomarkers for Clinical Diagnosis

Table 13 : Global Biomarkers Market, by Application Sector, Through 2023

Table 14 : Examples of Biomarkers Market Participants

Table 15 : Overview of Common Payment Forms in Licensing Deal

Table 16 : Number of Biomarker Licensing Deals in Different Biotech Sectors, 2008-2018

Table 17 : Share of Biomarker Licensing Deals in Different Biotech Sectors, by Year, 2008-2018

Table 18 : Example of Licensing Deals, 2008-2018

Table 19 : Number of Biomarker Licensing Deals in Different Pathological Sectors, 2008-2018

Table 20 : Share of Biomarker Licensing Deals in Different Pathological Sectors, 2008-2018

Table 21 : Purpose of Biomarker Licensing Deals, 2008-2018

Table 22 : Share of Licensing Deals Between Companies and Academic Institutions vs. Between Two Companies, 2008-2018

Table 23 : Share of Biomarker Licensing Deals in North America vs. Europe, 2008-2018

Table 24 : Total Number of Biomarker Acquisition Deals in Different Biotech Sectors, 2008-2018

Table 25 : Share of Biomarker Acquisition Deals in Different Biotech Sectors, by Year, 2008-2018

Table 26 : Examples of Acquisition Deals, 2008-2018

Table 27 : Number of Biomarker Acquisition Deals in Different Pathological Sectors, 2008-2018

Table 28 : Share of Biomarker Acquisition Deals in Different Pathological Sectors, 2008-2018

Table 29 : Purpose of Biomarkers Acquisition Deals, 2008-2018

Table 30 : Share of Biomarker Acquisition Deals in North America Vs. Europe, 2008-2018

Table 31 : Total Number of Biomarker Collaboration Deals in Different Biotech Sectors, 2008-2018

Table 32 : Share of Biomarker Collaboration Deals in Different Biotech Sectors, by Year, 2008-2018

Table 33 : Examples of Partnership/Collaboration Deals in the Biomarkers Market, 2008-2018

Table 34 : Number of Biomarker Collaboration Deals in Different Pathological Sectors, 2008-2018

Table 35 : Share of Biomarker Collaboration Deals in Different Pathological Sectors, 2008-2018

Table 36 : Purpose of Biomarkers Collaboration Deals, 2008-2018

Table 37 : Share of Collaboration Deals Between Companies and Academic Institutions vs. Between Two Companies, 2008-2018

Table 38 : Share of Biomarker Collaborations/Partnerships in North America vs. Europe, 2008-2018

Table 39 : Examples of Upfront Payments in Licensing Deals, 2008-2018

Table 40 : Examples of Milestone and Royalty Payments in Licensing Deals, 2008-2018

Table 41 : Examples of Termination Condition in Licensing Biomarkers Deals, 2008-2018

Table 42 : Global Biomarkers Licensing Deals Market, 2014-2018

Table 43 : Examples of Acquisition Deals Values in the Biomarkers Market, 2008-2018

Table 44 : Global Value of Biomarkers Acquisition Deals, 2014-2018

Table 45 : Examples of Upfront Payments and Total Value in Collaboration Deals, 2008-2018

Table 46 : Share of Upfront Payments from Total Value in Collaboration Deals, 2008-2018

Table 47 : Examples of Milestones and Royalty Payments in Collaboration Deals, 2008-2018

Table 48 : Examples of Termination Conditions in Collaboration Biomarkers Deals, 2008-2018

Table 49 : Global Value of Biomarkers Partnership Deals, 2014-2018

Table 50 : Examples of Biomarker Market Participants in Licensing, Collaboration and Acquisition Deals, 2008-2018

Table 51 : Examples of Biomarker Market Participants and Total Number of Deals Related to Biomarker Activity, 2008-2018

Table 52 : Financial Data for Qiagen, 2015-2017

Table 53 : Financial Data for bioMérieux, 2015-2017

Table 54 : Financial Data for MDxHealth, 2015-2017

Table 55 : Financial Data for Myriad Genetics, 2015-2017

Table 56 : Statistics for Prostate Cancer, 2017

Table 57 : Global Prostate Cancer Diagnostics Market and Related Cost, 2018-2023

Table 58 : Statistics for Breast Cancer, 2017

Table 59 : Global Market for Breast Cancer Diagnostics, Through 2019

Table 60 : Statistics for Bladder Cancer, 2017

Table 61 : Global Market for Bladder Cancer Diagnostics, 2017

Table 62 : Statistics for Ovarian Cancer, 2017

Table 63 : Global Ovarian Cancer Diagnostics Market, 2017

Table 64 : Statistics for Lung Cancer, 2017

Table 65 : Global Lung Cancer Diagnostics Market, 2017

Table 66 : U.S. Statistics Data for Alzheimer’s, 2017

Table 67 : Global Market for Alzheimer’s Disease Therapeutics and Diagnostics, Through 2020

Table 68 : U.S. Statistics Data for Cardiovascular Diseases, 2017

Table 69 : Global Cardiovascular Diagnostics Market, 2017

Table 70 : Global Organ and Tissue Transplantation Products and Devices Market, Through 2020

Table 71 : Number of Clinical Trials on Biomarkers Per Year, 2008-2017

Table 72 : Search Analysis for Clinical Trials Using Specific Keywords

Table 73 : Distribution of Clinical Trials on Biomarkers Based on Different Stages of Clinical Trials

Table 74 : Analysis of Biomarker Clinical Trials, Based on Sponsor

Table 75 : Examples of Clinical Trials Related to Biomarker R&D

Table 76 : Number of Clinical Trials Sponsored by Some Biomarker Market Participants

Table 77 : Number of Patents and Patent Applications Filed on Biomarkers, by Year, 2008-2017

Table 78 : Examples of Patents and Patent Applications Filed on Biomarkers, 2008-2017

Table 79 : Search Analysis for Patents and Patent Applications Using Keyword Combinations

Table 80 : Number of Patents and Patent Applications, by Company

Table 81 : Examples of Patents and Patent Applications Filed on Biomarkers, by Company

Table 82 : Global Value of Biomarkers Licensing, Acquisition and Partnership Deals, by Type, 2014-2018

Table 83 : Share of Biomarker Licensing Deals in Different Pathological Sectors, 2008-2018

Table 84 : Examples of Biomarker Market Participants and Total Number of Deals Related to Biomarker ActivityList of Figures

Summary Figure : Global Biomarkers Licensing, Acquisition and Partnership Deals Market, by Type, 2014-2018

Figure 1 : Schematic Presentation of Biomarker Development Process During Drug Development

Figure 2 : Global Biomarkers Market, 2016-2023

Figure 3 : Number of Biomarker Licensing Deals in Different Biotech Sectors, 2008-2018

Figure 4 : Share of Biomarker Licensing Deals in Different Biotech Sectors, by Year, 2008-2018

Figure 5 : Share of Biomarker Licensing Deals in Different Pathological Sectors, 2008-2018

Figure 6 : Purpose of Biomarker Licensing Deals, 2008-2018

Figure 7 : Share of Licensing Deals Between Companies and Academic Institutions vs. Between Two Companies, 2008-2018

Figure 8 : Share of Biomarker Licensing Deals in North America vs. Europe, 2008-2018

Figure 9 : Total Number of Biomarker Acquisition Deals in Different Biotech Sectors, 2008-2018

Figure 10 : Share of Biomarker Acquisition Deals in Different Biotech Sectors, by Year, 2008-2018

Figure 11 : Share of Biomarker Acquisition Deals in Different Pathological Sectors, 2008-2018

Figure 12 : Purpose of Biomarkers Acquisition Deals, 2008-2018

Figure 13 : Share of Biomarker Acquisition Deals in North America Vs. Europe, 2008-2018

Figure 14 : Total Number of Biomarker Collaboration Deals in Different Biotech Sectors, 2008-2018

Figure 15 : Share of Biomarker Collaboration Deals in Different Biotech Sectors, by Year, 2008-2018

Figure 16 : Share of Biomarker Collaboration Deals in Different Pathological Sectors, 2008-2018

Figure 17 : Purpose of Biomarkers Collaboration Deals, 2008-2018

Figure 18 : Share of Collaboration Deals Between Companies and Academic Institutions vs. Between Two Companies, 2008-2018

Figure 19 : Share of Biomarker Collaboration/Partnerships in North America vs. Europe, 2008-2018

Figure 20 : Global Biomarkers Licensing Deals Market, 2014-2018

Figure 21 : Global Biomarkers Acquisition Deals Market, 2014-2018

Figure 22 : Global Biomarkers Partnership Deals Market, 2014-2018

Figure 23 : Examples of Biomarker Market Participants and Total Number of Deals Related to Biomarker Activity, 2008-2018

Figure 24 : Number of Clinical Trials on Biomarkers Per Year, 2008-2017

Figure 25 : Search Analysis for Clinical Trials Using Specific Keywords

Figure 26 : Distribution of Clinical Trials on Biomarkers Based on Different Stages of Clinical Trials

Figure 27 : Number of Patents and Patent Applications Filed on Biomarkers, by Year, 2008-2017

Figure 28 : Search Analysis for Patents and Patent Applications Using Keyword Combinations

Figure 29 : Global Biomarkers Licensing, Acquisition and Partnership Deals Market, by Type, 2014-2018